Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Moshe C Ornstein

Showing results (11-20 of 61) with videos related to

Pageof 7
Sort By:
Cancer Management and Research|July 2, 2020
Ipilimumab and Nivolumab as First-Line Treatment of Patients with Renal Cell Carcinoma: The Evidence to DateIris Y Sheng, Moshe C Ornstein
Urologic Oncology|September 12, 2017
Emerging immunotherapy in advanced renal cell carcinomaPrateek Mendiratta, Brian I Rini, Moshe C Ornstein
Best Practice & Research. Clinical Haematology|February 10, 2015
More is better: combination therapies for myelodysplastic syndromesMoshe C Ornstein, Sudipto Mukherjee, Mikkael A Sekeres
Cancer Treatment and Research Communications|March 4, 2020
The role of active surveillance and cytoreductive nephrectomy in metastatic renal cell carcinomaAmanda Nizam, Jonah A Schindelheim, Moshe C Ornstein
Journal for Immunotherapy of Cancer|October 2, 2021
Treatment-free survival after discontinuation of immune checkpoint inhibitors in metastatic renal cell carcinoma: a systematic review and meta-analysisAlice Tzeng, Tony H Tzeng, Moshe C Ornstein
Current Oncology (Toronto, Ont.)|June 2, 2021
Cytoreductive Nephrectomy Following Immunotherapy-Base Treatment in Metastatic Renal Cell Carcinoma: A Case Series and Review of Current LiteratureScott J Dawsey, Steven C Campbell, Moshe C Ornstein
Journal of Kidney Cancer and VHL|July 21, 2017
The Evolving Treatment Landscape of Advanced Renal Cell Carcinoma in Patients Progressing after VEGF InhibitionPedro C Barata, Moshe C Ornstein, Jorge A Garcia
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|October 13, 2020
The Immunotherapy Landscape in Renal Cell CarcinomaLandon C Brown, Kunal Desai, Tian Zhang, et al.
Case Reports in Oncological Medicine|July 9, 2019
Tailoring Immunotherapy Treatment of Synchronous Renal Cell Carcinoma (RCC) and Triple-Negative Breast Cancer (TNBC)Iris Y Sheng, Megan Kruse, Kathryn M Leininger, et al.
Therapeutics and Clinical Risk Management|June 13, 2018
Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlookDharmesh Gopalakrishnan, Vadim S Koshkin, Moshe C Ornstein, et al.
Pageof 7

Showing results (11-20 of 61) with videos related to

Sort By:
Pageof 7
Cancer Management and Research|July 2, 2020
Ipilimumab and Nivolumab as First-Line Treatment of Patients with Renal Cell Carcinoma: The Evidence to DateIris Y Sheng, Moshe C Ornstein
Urologic Oncology|September 12, 2017
Emerging immunotherapy in advanced renal cell carcinomaPrateek Mendiratta, Brian I Rini, Moshe C Ornstein
Best Practice & Research. Clinical Haematology|February 10, 2015
More is better: combination therapies for myelodysplastic syndromesMoshe C Ornstein, Sudipto Mukherjee, Mikkael A Sekeres
Cancer Treatment and Research Communications|March 4, 2020
The role of active surveillance and cytoreductive nephrectomy in metastatic renal cell carcinomaAmanda Nizam, Jonah A Schindelheim, Moshe C Ornstein
Journal for Immunotherapy of Cancer|October 2, 2021
Treatment-free survival after discontinuation of immune checkpoint inhibitors in metastatic renal cell carcinoma: a systematic review and meta-analysisAlice Tzeng, Tony H Tzeng, Moshe C Ornstein
Current Oncology (Toronto, Ont.)|June 2, 2021
Cytoreductive Nephrectomy Following Immunotherapy-Base Treatment in Metastatic Renal Cell Carcinoma: A Case Series and Review of Current LiteratureScott J Dawsey, Steven C Campbell, Moshe C Ornstein
Journal of Kidney Cancer and VHL|July 21, 2017
The Evolving Treatment Landscape of Advanced Renal Cell Carcinoma in Patients Progressing after VEGF InhibitionPedro C Barata, Moshe C Ornstein, Jorge A Garcia
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|October 13, 2020
The Immunotherapy Landscape in Renal Cell CarcinomaLandon C Brown, Kunal Desai, Tian Zhang, et al.
Case Reports in Oncological Medicine|July 9, 2019
Tailoring Immunotherapy Treatment of Synchronous Renal Cell Carcinoma (RCC) and Triple-Negative Breast Cancer (TNBC)Iris Y Sheng, Megan Kruse, Kathryn M Leininger, et al.
Therapeutics and Clinical Risk Management|June 13, 2018
Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlookDharmesh Gopalakrishnan, Vadim S Koshkin, Moshe C Ornstein, et al.
Pageof 7